Trade Entasis Therapeutics Holdings Inc. - ETTX CFD
Add to favourite- Summary
- Historical Data
- Events
- Ownership
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 1.40-3.88 |
| Average Volume (10 days) | N/A |
| Average Volume (3 months) | 4.59M |
| Market Cap | 104.80M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 47.85M |
| Revenue | N/A |
| EPS | -1.13 |
| Dividend (Yield %) | N/A |
| Beta | 1.32 |
| Next Earnings Date | Aug 9, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Entasis Therapeutics Holdings Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Entasis Therapeutics Holdings Inc. Company profile
About Entasis Therapeutics Holdings Inc
Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Entasis Therapeutics Holdings Inc revenues was not reported. Net loss decreased 7% to $47.1M. Lower net loss reflects Research and development - Balancing va decrease of 11% to $35.2M (expense), Grant income increase of 45% to $5.2M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$1.09.
| Industry: | Bio Therapeutic Drugs |
35 Gatehouse Drive
WALTHAM
MASSACHUSETTS 02451
US
News
Gold price predictions for next 5 years: Will gold continue rising amid banking fallout?
The yellow metal started 2023 with a bang, yet will it maintain the momentum and for how long?
17:55, 21 March 2023
Cardano price prediction: What is next for ADA?
Can ADA capitalise on a recent price boost?
15:44, 21 March 2023
Nvidia shows off work with AT&T, quantum computing firms at AI conference
Adds details from keynote
15:29, 21 March 2023
ECB tells banks to watch their cash amid turmoil
Adds Enria's comments in parliament
15:27, 21 March 2023
TotalEnergies sticks to 2030 goal for Scope 3 emissions
Adds details, graphic
15:22, 21 March 2023
US home sales surge; house prices post year-on-year drop
Existing home sales jump 14.5% in February
15:21, 21 March 2023
U.S. FDA to soon decide on second round of Omicron-tailored boosters - WSJ
Adds details from report
15:08, 21 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com